Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04486781 · ClinicalTrials.gov registry record · Phase 2
A Study of Pembrolizumab+ sEphB4 in Metastatic Urothelial Carcinoma
A Phase 2 study of Metastatic Urothelial Carcinoma, sponsored by Vasgene Therapeutics.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 38
- Enrollment target
- 1
- Study location
NCT04486781: Recruiting Phase 2 study of Metastatic Urothelial Carcinoma, sponsored by Vasgene Therapeutics.
NCT04486781 is a Phase 2 study of Metastatic Urothelial Carcinoma that is actively recruiting participants, run by Vasgene Therapeutics. The registered enrollment target is 38 participants, below the 129-participant average among 30 other Metastatic Urothelial Carcinoma trials with a reported enrollment target (71% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04486781, a Phase 2 study of Metastatic Urothelial Carcinoma, is actively recruiting participants, sponsored by Vasgene Therapeutics.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 38 participants
- Enrollment target
- 1
- Study location
Study Summary
sEphB-HSA may prevent tumor cells from multiplying and blocks several compounds that promote the growth of blood vessels that bring nutrients to the tumor. The purpose of this study is to evaluate the combination of Pembrolizumab + sEphB4-HSA in the population of patients with previously untreated advanced (metastatic or recurrent) urothelial carcinoma who are chemotherapy ineligible or who refuse chemotherapy.
Conditions Studied
Interventions
- DRUG Pembrolizumab + sEphB4-HSA
Study Locations (1)
California
- Sarcoma Oncology Center - Santa Monica
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 38 participants |
| Start Date | 2020-08-14 |
| Est. Completion | 2025-12-31 |
| Phase | Phase 2 |
What NCT04486781 shows while recruiting
NCT04486781 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 38 participants, a relatively small participant target, below the 129-participant average among 30 other Metastatic Urothelial Carcinoma trials with a reported enrollment target (71% lower).
The record links to 1 condition, with Metastatic Urothelial Carcinoma appearing as the primary indexed condition, and to 1 intervention - of which Pembrolizumab + sEphB4-HSA is the first listed.
NCT04486781 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT04486781 about?
NCT04486781 is a clinical study titled "A Study of Pembrolizumab+ sEphB4 in Metastatic Urothelial Carcinoma". sEphB-HSA may prevent tumor cells from multiplying and blocks several compounds that promote the growth of blood vessels that bring nutrients to the tumor. The purpose of this study is to evaluate the combination of Pembrolizumab + sEphB4-HSA in the population of patients with previously untreated a...
What is the current status of trial NCT04486781?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 38 participants. The study started on 2020-08-14. Estimated completion is 2025-12-31.
What conditions does trial NCT04486781 study?
This clinical trial studies the following conditions: Metastatic Urothelial Carcinoma.
What interventions are being tested in trial NCT04486781?
The interventions under investigation include: Pembrolizumab + sEphB4-HSA (DRUG).
Who is sponsoring clinical trial NCT04486781?
This trial is sponsored by Vasgene Therapeutics, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04486781 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastatic Urothelial Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04486781's enrollment target sits among peer trials
38 19th of 30 higher than 11 of 30 other Metastatic Urothelial Carcinoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Metastatic Urothelial Carcinoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors
RECRUITING · Phase 2
-
Pembrolizumab Maintenance After Enfortumab Vedotin (EV)/Pembro Induction in Front-Line Metastatic Urothelial Carcinoma
RECRUITING · Phase 2
-
Modular Trial of sEphB4-HSA in EphrinB2-High Solid Tumors
RECRUITING · Phase 2
-
ARID1A and/or KDM6A Mutation and CXCL13 Expression
ACTIVE NOT RECRUITING · Phase 2
-
Immune Checkpoint Inhibitors With or Without Propranolol Hydrochloride In Patients With Urothelial Carcinoma
ACTIVE NOT RECRUITING · Phase 2
-
Sapanisertib in Treating Patients With Locally Advanced or Metastatic Bladder Cancer With TSC1 and/or TSC2 Mutations
ACTIVE NOT RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01684904 · 38 participants · NA
Proton Therapy for Esophageal Cancer
- NCT03310879 · 38 participants · Phase 2
Study of the CDK4/6 Inhibitor Abemaciclib in Solid Tumors Harboring Genetic Alterations in Genes Encoding D-Type Cyclins or Amplification of CDK4 or CDK6
- NCT03896269 · 38 participants · Phase 1
CPX-351 in Treating Patients With Relapsed or Refractory High Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia
- NCT04085315 · 38 participants · Phase 1
Alisertib in Combination With Osimertinib in Metastatic EGFR-mutant Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI